XML 42 R28.htm IDEA: XBRL DOCUMENT v3.26.1
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Mar. 31, 2026
Stockholders' Equity Note [Abstract]  
Schedule of Compensation Cost on Net Earnings
The Company’s results for the three months ended March 31, 2026 and 2025 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

Increase/(Decrease) for the
Three Months Ended March 31,
20262025
Cost of sales$531 $438 
Operating expenses4,825 3,372 
Net earnings(4,120)(2,928)
Schedule of Stock Option Activity
Option activity for the three months ended March 31, 2026 and 2025 is summarized below:
For the Three Months Ended March 31, 2026Shares (000s)Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding as of December 31, 2025900 $120.48 $29,888 
Granted71 178.68 
Exercised(66)101.52 
Forfeited— — 
Canceled(2)139.31 
Outstanding as of March 31, 2026903 $126.38 $39,577 5.5
Exercisable as of March 31, 2026653 $114.89 $35,662 4.5
For the Three Months Ended March 31, 2025Shares (000s)Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding as of December 31, 2024962 $114.81 $46,346 
Granted51 159.18 
Exercised(18)90.50 
Forfeited— — 
Canceled— — 
Outstanding as of March 31, 2025995 $117.53 $48,212 5.6
Exercisable as of March 31, 2025688 $105.78 $41,408 4.4
Schedule of Assumptions Used in the Valuation of Option Awards For the three months ended March 31, 2026, the fair value of each option grant was estimated on the date of the grant using the following weighted average assumptions:
 Three Months Ended March 31,
 20262025
Dividend yields0.5 %0.6 %
Expected volatilities23.5 %26.0 %
Risk-free interest rates3.8 %4.5 %
Expected lives5.2 years5.2 years
A Monte-Carlo simulation has been used to estimate the fair value using the following assumptions:
 Three Months Ended March 31,
 20262025
Dividend yields— %— %
Expected volatilities22.8 %25.5 %
Risk-free interest rates3.5 %4.3 %
Initial TSR's16.0 %-8.8 %
Schedule of Other Information Pertaining to Stock Option Activity
Other information pertaining to option activity during the three months ended March 31, 2026 and 2025 is as follows:

 Three Months Ended March 31,
 20262025
Weighted-average fair value of options granted$48.90 $48.86 
Total intrinsic value of stock options exercised ($000s)$4,754 $1,388 
Schedule of Non-vested Restricted Stock Activity
Non-vested restricted stock activity for the three months ended March 31, 2026 and 2025 is summarized below:
Three Months Ended March 31,
20262025
Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance as of December 31147 $150.15 122 $141.62 
Granted59 178.34 54 159.11 
Vested(50)145.25 (28)138.21 
Forfeited(1)155.53 (1)140.76 
Non-vested balance as of March 31155 $162.45 147 $148.68 
Schedule of Non-vested Performance Share Activity
Non-vested performance share activity for the three months ended March 31, 2026 and 2025 is summarized below:

Three Months Ended March 31,
20262025
Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance as of December 3181 $160.14 79 $150.73 
Granted50 173.60 50 147.96
Vested(35)148.64 (44)109.95
Forfeited— — (4)150.11
Non-vested balance as of March 3196 $171.52 81 $160.14